Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. 2007

Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
Department of Breast Surgery, Cancer Hospital, Cancer Institute, Fudan University, Shanghai 200032, PR China.

Estrogen receptor (ER) status can predict the efficacy of endocrine therapy. However, the predictive significance of the progesterone receptor (PgR) is controversial in an adjuvant setting. Records of 758 ER+ breast cancer patients who received adjuvant tamoxifen (TAM) for 3-5 years were reviewed to evaluate the predictive value of PgR for TAM treatment in ER+/PgR+ and ER+/PgR- groups. By a median of 40 months' follow-up, there was no significant difference between the two groups with regard to disease-free-survival (DFS). On the basis of STEPP analysis showing the tendency of age effect on DFS in both the ER+/PgR- and ER+/PgR+ groups, we classified the ER+ patients into three strata by age (<45, 45-60, and >or=60 years). There was no significant difference in DFS and overall survival (OS) between the two groups in the <45 stratum and the 45-60 stratum. In contrast, the ER+/PgR- group had a worse prognosis in the >or=60 stratum with regard to both DFS (P=0.0484) and OS (P=0.0009). The results suggest that PgR status might be a predictive factor of benefit to be gained from adjuvant TAM for older ER+ patients with regard to DFS and OS. This should take into account older ER+/PgR- patients who tend to be resistant to TAM.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
May 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
August 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
December 2022, Breast (Edinburgh, Scotland),
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
February 2014, Canadian journal of surgery. Journal canadien de chirurgie,
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
April 2011, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
October 2021, Cancers,
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
June 2020, Chinese clinical oncology,
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
June 2020, Chinese clinical oncology,
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
July 2012, Acta oncologica (Stockholm, Sweden),
Ke-Da Yu, and Guang-Yu Liu, and Gen-Hong Di, and Jiong Wu, and Jin-Song Lu, and Kun-Wei Shen, and Zhen-Zhou Shen, and Zhi-Ming Shao
October 2023, Annals of surgical oncology,
Copied contents to your clipboard!